---
title: 'Senior Director, Global Market Access at Cogent Biosciences'
canonical: 'https://feeny.ai/job/senior-director-global-market-access-cogent-biosciences-waltham-ryr14ebyxz55'
type: 'job'
last_seen: '2026-10-14'
---

# Senior Director, Global Market Access at Cogent Biosciences

- **Company:** Cogent Biosciences
- **Location:** Waltham, MA
- **Posted:** 2026-09-29
- **Last confirmed live:** 2026-10-14
- **Apply:** https://job-boards.greenhouse.io/cogentbiosciences/jobs/4424700009

## Job description

Who We Are:

Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has exhibited promising initial data across all three trials: APEX in AdvSM, SUMMIT in NonAdvSM and PEAK in GIST, including an encouraging safety profile across 600+ patients in single agent and combination dosing.

The Role:

Cogent Biosciences is seeking an entrepreneurial and strategic Senior Director, Global Market Access to develop and execute market access strategies that enable patients with cancer to access innovative therapies.

Reporting to the Vice President, Value & Access Strategy, this role will have a global remit with some responsibility for the US market. The Sr. Director will work across the organization to translate clinical and economic value into compelling market access strategies across key markets.

The role will partner closely with Commercial, Medical Affairs, Clinical Development, Regulatory, Finance, and other cross-functional teams, while working closely with the company's HEOR capabilities within the Value & Access organization to develop evidence and value strategies that support payer and HTA decision-making.

The ideal candidate brings strong oncology market access experience, a solid understanding of payer and reimbursement dynamics, and experience developing access strategies across international markets. This is a highly visible, hands-on role in a growing biotech environment, requiring both strategic thinking and the ability to drive execution with lean internal resources and external partners.

## Responsibilities

Global Market Access & Value Strategy

- Develop and execute global market access strategies for oncology pipeline and commercial products across the product lifecycle.
- Identify market access opportunities, risks, and potential barriers across the US and priority international markets.
- Develop market-specific strategies informed by payer dynamics, reimbursement and HTA requirements, clinical practice, treatment pathways, and competitive landscapes.
- Integrate market access, pricing, reimbursement, HEOR, and value considerations into broader product, development, and commercialization strategies.
- Monitor changes in oncology treatment, reimbursement, and health-system environments and assess implications for the portfolio.

Evidence, HEOR & Oncology Value Strategy

- Lead the integration of market access and HEOR perspectives into the overall value strategy for oncology assets.
- Translate the clinical profile, unmet need, and treatment landscape into differentiated payer and HTA value propositions.
- Partner closely with HEOR and Medical Affairs to define evidence requirements and develop evidence-generation strategies across key markets.
- Provide market access input into clinical development plans, endpoints, comparators, patient populations, and evidence-generation priorities.
- Identify evidence gaps that may create future access barriers and work with HEOR and cross-functional teams to address them.
- Guide development of value dossiers, economic models, budget impact analyses, and other market access tools in partnership with HEOR.
- Ensure HEOR outputs are effectively translated into payer, HTA, and broader market access strategies.

Pricing & Reimbursement

- Develop and support global pricing and reimbursement strategies in partnership with the VP, Value & Access Strategy and cross-functional stakeholders.
- Conduct pricing and reimbursement assessments across priority markets, considering clinical value, treatment alternatives, healthcare-system dynamics, and market access requirements.
- Develop pricing scenarios and assumptions to support business planning, forecasting, and strategic decision-making.
- Ensure pricing considerations are appropriately integrated with the overall value and access strategy throughout the product lifecycle.

Launch Readiness

- Serve as a core market access leader within cross-functional launch teams.
- Develop market access launch plans, milestones, risks, and mitigation strategies.
- Incorporate payer, reimbursement, pricing, HTA, and evidence considerations into launch sequencing and commercialization planning.
- Support development of payer-facing materials and value communication tools.
- Help establish appropriate access metrics and readiness assessments.
- Ensure the organization is prepared to address market access considerations in key launch markets.

## Qualifications

- Bachelor’s degree in a relevant discipline; advanced degree preferred (e.g., MBA, MPH, PharmD, MS).
- 10+ years of experience in pharmaceutical or biotechnology market access, pricing, reimbursement, HEOR, or a related discipline.
- Demonstrated experience developing market access strategies in the US and international markets.
- Experience in oncology, specialty pharmaceuticals, or other complex therapeutic areas.
- Experience supporting products through development and/or commercialization, ideally including a launch.
- Experience translating clinical evidence and product value into payer and HTA strategies.
- Understanding of global pricing, reimbursement, and HTA environments.
- Strong analytical, strategic planning, project management, and communication skills.

Salary Range:

$260,000 to $305,000 USD

Target Bonus: 25%

Exact compensation will vary based on skills, experience, and location.

Our Locations

Waltham, MA: Our headquarters is located in the Greater Boston life sciences community, with an open, collaborative office environment designed to support teamwork and connection. Employees benefit from convenient on-site amenities, including free on-site parking and gym facilities in the building.

Boulder, CO: Our Boulder location is home to Cogent’s discovery research organization and a key scientific hub with strong leadership based on site. Situated in the greater Denver-Boulder biopharmaceutical corridor, this office plays a central role in advancing our discovery efforts and pipeline.

Our Offer To You

At Cogent Biosciences, we offer a competitive salary, bonus, and ongoing stock awards, alongside a benefits package that sets us apart. We cover 100% of medical, dental, and vision premiums for you and your family, and help reduce out-of-pocket costs by funding up to 75% of in-network deductibles. Our benefits also include a 401(k) match with immediate vesting, generous paid time off, 12 weeks of fully paid parental leave, paid family and medical leave for all employees regardless of location, and company-paid short-term disability coverage for up to 20 weeks. Additional perks like wellness programs, tuition reimbursement, and inclusive family-forming support help you thrive at work and beyond.

We are proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability, or any other status protected under federal, state, or local law. All employment is decided on the basis of qualifications, merit, and business need.

## About Cogent Biosciences

## Company Overview
- **One-liner**: Cogent Biosciences is a publicly traded biotechnology company developing precision therapies for genetically defined diseases, with its lead program bezuclastinib targeting KIT D816V mutations in systemic mastocytosis and gastrointestinal stromal tumors.
- **Entity Type**: Public (NASDAQ: COGT)
- **Headquarters**: Waltham, Massachusetts, United States (with additional office in Boulder, Colorado)
- **Founded**: 2014
- **Founders**: Not publicly available

## Core Business
- **Primary industry**: Biotechnology research and therapeutics development
- **Target customers**: Patients with genetically defined diseases, healthcare providers, and pharmaceutical partners (B2B/B2C hybrid)
- **Mission**: “To discover, develop, and commercialize best-in-class therapies that have a dramatic impact for patients with genetically defined diseases” [cogentbio.com](https://www.cogentbio.com/)

## Products & Services
- **Bezuclastinib**: A selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation and other KIT exon 17 mutations. In late-stage clinical development for advanced systemic mastocytosis (AdvSM), non‑advanced SM, and advanced gastrointestinal stromal tumors (GIST). Positive registration‑directed trial results reported in 2025. [greenhouse.io](https://job-boards.greenhouse.io/cogentbiosciences)
- **Novel JAK2 V617F inhibitor**: A potential best‑in‑class mutant‑selective JAK2 inhibitor currently in preclinical development, with data presented at the 2026 EHA Congress. [cogentbio.com](https://www.cogentbio.com/)
- **Additional pipeline programs**: Research‑stage targeted therapies addressing mutations in ErbB2, PI3Kα, KRAS, and JAK2. [greenhouse.io](https://job-boards.greenhouse.io/cogentbiosciences)

## Market Standing
- **Valuation/Market Cap**: USD $762.7 million (as of mid‑2026, based on LinkedIn data) [linkedin.com](https://www.linkedin.com/company/cogentbiosciences)
- **Key Metric**: Annual revenue of USD $7.9 million (likely from partnerships or grants); total funding to date ~USD $1.82 billion (including post‑IPO equity, debt, and Series A). [linkedin.com](https://www.linkedin.com/company/cogentbiosciences)
- **Notable Investors/Partners**: Series A led by Atlas Venture and F‑Prime; post‑IPO equity rounds led by Commodore Capital (2024, $225M), Fairmount Funds Management (2020, $104.4M) [linkedin.com](https://www.linkedin.com/company/cogentbiosciences)
- **Growth Signals**: Headcount grew 27.6% year‑over‑year to 223 employees; monthly LinkedIn follower growth of 3.0% (+61.7% annually); positive late‑stage trial results in 2025; expanded pipeline with new preclinical assets. [linkedin.com](https://www.linkedin.com/company/cogentbiosciences)

## Competitive Advantages
- **Selective targeting of KIT D816V**: Bezuclastinib is designed to selectively and potently inhibit the key driver mutation in systemic mastocytosis, potentially offering a better safety/tolerability profile than earlier multi‑kinase inhibitors.
- **Late‑stage momentum**: Registration‑directed trials (APEX pivotal trial) have reported clinically meaningful results, positioning the company for potential regulatory submissions and commercialization.
- **Broad pipeline beyond KIT**: Research into JAK2, KRAS, PI3Kα, and ErbB2 mutations diversifies the platform and reduces single‑asset risk.
- **Strong capital position**: Over $760M market cap and access to public equity markets provide financial runway for multiple programs.

## Strategic Focus
- **Advance bezuclastinib to market**: Continue regulatory interactions and preparation for potential FDA approval in AdvSM and GIST, while expanding into non‑advanced SM.
- **Build a portfolio of precision therapies**: Invest in early‑stage discovery (Boulder, CO) to generate novel molecules targeting validated oncogenic drivers.
- **Commercial readiness**: Hiring commercial leadership (Chief Commercial Officer, Market Access, Field Medical Affairs) indicates preparation for a future product launch. [greenhouse.io](https://job-boards.greenhouse.io/cogentbiosciences)

## Why Work Here
- **Culture**: Emphasizes collaboration, urgency, inquisitiveness, and ingenuity. Corporate values include “Patients are waiting” (urgency), “Learning excites us” (inquisitiveness), “Succeed Together” (trust), and “Navigate uncertainty” (ingenuity). [cogentbio.com](https://www.cogentbio.com/careers/)
- **Work model**: Hybrid/remote flexibility – many roles are listed as remote (e.g., Area Directors for Field Medical Affairs, Patient Educators), while research roles are onsite in Boulder, CO. [greenhouse.io](https://job-boards.greenhouse.io/cogentbiosciences)
- **Growth and impact**: As a late‑stage clinical company with an expanding pipeline, employees have direct influence on programs that could change patient lives. Fast‑paced environment with high autonomy.

## Sources
1. [Cogent Biosciences Corporate Website](https://www.cogentbio.com/)
2. [Cogent Biosciences About Page](https://www.cogentbio.com/about/)
3. [Cogent Biosciences Careers Page](https://www.cogentbio.com/careers/)
4. [Cogent Biosciences Job Board (Greenhouse)](https://job-boards.greenhouse.io/cogentbiosciences)
5. [Cogent Biosciences LinkedIn Profile](https://www.linkedin.com/company/cogentbiosciences)

## Other roles at Cogent Biosciences

- [Associate Director, Accounting Operations](https://feeny.ai/job/associate-director-accounting-operations-cogent-biosciences-waltham-mnsd4hanythw) — Waltham, MA
- [Associate Director, Training and Contract Operations](https://feeny.ai/job/associate-director-training-and-contract-operations-cogent-biosciences-waltham-0batp7n1zpdd) — Waltham, MA
- [Senior Associate, Pharmacovigilance Coordinator](https://feeny.ai/job/senior-associate-pharmacovigilance-coordinator-cogent-biosciences-waltham-605v8frhmdj6) — Waltham, MA
- [Manager, Cost Accounting](https://feeny.ai/job/manager-cost-accounting-cogent-biosciences-waltham-r0e52v91m7rb) — Waltham, MA
- [Scientist, DMPK (BioAnalytical and Medical Writing)](https://feeny.ai/job/scientist-dmpk-bioanalytical-and-medical-writing-cogent-biosciences-boulder-r2b31gdpf60e) — Boulder, CO
- [Director, National Payer Accounts](https://feeny.ai/job/director-national-payer-accounts-cogent-biosciences-waltham-5jkvd1gj4bg7) — Waltham, MA
- [Director, Patient Advocacy & Engagement](https://feeny.ai/job/director-patient-advocacy-engagement-cogent-biosciences-waltham-mdfqz22t61ny) — Waltham, MA
- [Manager, Communications and Investor Relations](https://feeny.ai/job/manager-communications-and-investor-relations-cogent-biosciences-waltham-am68edvhn0v0) — Waltham, MA
- [Associate Director, Translational Medicine](https://feeny.ai/job/associate-director-translational-medicine-cogent-biosciences-waltham-rj8yex8parvp) — Waltham, MA
- [Director, Corporate Counsel](https://feeny.ai/job/director-corporate-counsel-cogent-biosciences-waltham-re6398tj5cwt) — Waltham, MA